Literature DB >> 3093049

Pathophysiology of malnutrition in the adult cancer patient.

D Heber, L O Byerley, J Chi, M Grosvenor, R N Bergman, M Coleman, R T Chlebowski.   

Abstract

A number of common metastatic cancers are associated with marked weight loss at the time of diagnosis. Cancer patients with weight loss at the time of diagnosis have decreased mean survival compared to similar cancer patients without weight loss. Provision of excess calories alone does not appear to change median survival in patients with advanced cancer and many patients either maintain body weight or lose weight while receiving calories which would be predicted to result in weight gain. The authors recently have extended their studies to head and neck cancer patients without detectable metastatic disease in order to detect systemic metabolic effects of a localized tumor. These patients failed to gain weight despite the administration of apparently adequate calories by continuous enteral alimentation. Abnormalities of carbohydrate metabolism with secondary effects on fat and protein metabolism have been identified in several populations of patients with common cancers. These abnormalities offer potential points of intervention which may enhance nutritional therapy as rehabilitation and as a potential biological modifier of the response of specific cancers to chemotherapy, radiation therapy, or surgery.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093049     DOI: 10.1002/1097-0142(19861015)58:8+<1867::aid-cncr2820581413>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Managing cancer-related anorexia/cachexia.

Authors:  G Mantovani; A Macciò; E Massa; C Madeddu
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Metabolic alteration in patients with cancer: nutritional implications.

Authors:  Y Sakurai; S Klein
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 3.  Nutrition in cancer patients.

Authors:  S Mercadante
Journal:  Support Care Cancer       Date:  1996-01       Impact factor: 3.603

4.  Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.

Authors:  Giovanni Mantovani; Antonio Macciò; Clelia Madeddu; Roberto Serpe; Elena Massa; Mariele Dessì; Filomena Panzone; Paolo Contu
Journal:  Oncologist       Date:  2010-02-15

5.  Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region.

Authors:  M J Bruno; E B Haverkort; G P Tijssen; G N Tytgat; D J van Leeuwen
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

Review 6.  Ethical dilemmas in hospice and palliative care.

Authors:  B M Kinzbrunner
Journal:  Support Care Cancer       Date:  1995-01       Impact factor: 3.603

7.  Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.

Authors:  Giovanni Mantovani; Antonio Macciò; Clelia Madeddu; Roberto Serpe; Giorgia Antoni; Elena Massa; Mariele Dessì; Filomena Panzone
Journal:  J Mol Med (Berl)       Date:  2009-10-03       Impact factor: 4.599

Review 8.  Protein calorie malnutrition and cancer therapy.

Authors:  H L Parnes; J Aisner
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

9.  Effect of insulin on weight loss and tumour growth in a cachexia model.

Authors:  S A Beck; M J Tisdale
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

10.  Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.

Authors:  P Cariuk; M J Lorite; P T Todorov; W N Field; S J Wigmore; M J Tisdale
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.